- Title: Subtitle
- The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS)
- Creators
- Mrinal M. Gounder - Memorial Sloan Kettering Cancer CenterAndrew J. Wagner - Dana-Farber Cancer InstituteNeeta Somaiah - The University of Texas MD Anderson Cancer CenterRichard F. Riedel - Duke Medical CenterGary K. Schwartz - Columbia University Irving Medical CenterSteven Attia - Mayo Clinic in FloridaAlbiruni R.A. Razak - Princess Margaret Hospital, Toronto, ON, Canada;Lee D. Cranmer - University of ArizonaScott H. Okuno - Mayo ClinicMohammed M. Milhem - University of IowaCassandra Choe-Juliak - Karyopharm TherapeuticsSharon Shacham - Karyopharm TherapeuticsMichael G. Kauffman - Karyopharm TherapeuticsSant P. Chawla - Sarcoma Oncology Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.TPS11072-TPS11072
- DOI
- 10.1200/JCO.2016.34.15_suppl.TPS11072
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363459702771
Abstract
The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS)
Journal of clinical oncology, Vol.34(15_suppl), pp.TPS11072-TPS11072
05/20/2016
DOI: 10.1200/JCO.2016.34.15_suppl.TPS11072
Details
Metrics
13 Record Views